|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
ELDERS FORCE INDEX
Trading: BUY @ $46.99
Signal Strength: MEDIUM
Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.
Ra Pharmaceuticals Inc (NASDAQ:RARX) current price has highlighted recent buying pressure. Currently, the Elders Force Index is 17105.
Elders Force Index (EFI) measures the power behind a price movement using price and volume. The indicator can also be used to identify potential reversals and price corrections. The EFI is an oscillator that fluctuates between positive and negative values above and below a Zero Line.
Calculation: Elders Force Index (EFI):
1) Close – Close yesterday x Volume;
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|LSCC Lattice Semicond||23.34||9.7||7,172,000||-2,239||BEARISH|
|IIIN Insteel Industries||26.01||6.9||349,900||-73,055||BEARISH|
|VRAY Viewray Inc||3.12||6.8||5,344,700||-6,704||BEARISH|
|ADRO Aduro Biotech||1.4||4.5||927,400||-3,901||BEARISH|
|MERC Mercer Intl Inc||13.25||3.7||299,000||-24,892||BEARISH|
|ASNA Ascena Retail||6.5||3.5||328,800||-7,802||BEARISH|
|MIDD Middleby Corp||113.33||3.3||1,200,700||-102,290||BEARISH|
|PETS Petmed Express Inc||27.26||2.8||905,900||-113||BEARISH|
|RNET Rignet Inc||6.08||2.7||49,900||-3,595||BEARISH|